TUMOR, SOLID

This Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effe…

This early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…

This study tests whether a structured nutrition program can prevent malnutrition in children with solid tumors. About 400 children will receive a team-based nutrition plan including special diets. The goal is to improve weight, height, and overall health during treatment.

This study tests a new drug called CNSI-Fe(II), which is injected directly into tumors. It uses iron to trigger a type of cell death called ferroptosis, aiming to control advanced solid tumors like lung, pancreas, and colorectal cancers. The trial involves 54 adults whose current…

This early-stage study tests a personalized mRNA vaccine (RGL-270) in people with solid tumors who have a high chance of the cancer returning after standard treatment. The vaccine is designed to train the immune system to recognize and attack leftover cancer cells. Some participa…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This early-phase trial tests a personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The treatment involves collecting a patient's own immune cells, engineering them to recognize and attack cancer cells carrying the muta…

This early-phase trial tests a new type of cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recognize and attack c…

This early-stage study tests an experimental drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the drug behaves in the body. About 28 participants will take part to help guide future…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded t…

This early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…

This study tests a dye called indocyanine green that is injected into the blood before surgery. The dye makes tumors glow under a special camera, helping surgeons see and remove cancer that might otherwise be missed. The trial includes 500 adults with solid tumors who are schedul…

This study aims to find out if certain blood markers can predict how well cancer patients respond to immunotherapy. Researchers will collect blood samples from 1500 people with different types of cancer before and during treatment. Participants will be followed for up to 6 months…